Vectura Group PLC  

(Public, LON:VEC)   Watch this stock  
Find more results for VEC
118.38
+1.38 (1.18%)
Real-time:   2:42PM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 117.50 - 119.75
52 week 100.47 - 171.50
Open 119.75
Vol / Avg. 360,855.00/411,656.00
Mkt cap 476.41M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 402.46M
Beta     -
Inst. own     -
*GBP
Nov 18, 2014
Half Year 2014 Vectura Group PLC Earnings Release - 8:00AM GMT - Add to calendar
Sep 19, 2014
Vectura Group PLC Annual Shareholders Meeting
Aug 19, 2014
Vectura Group PLC Interim Management Statement for the period 1 April 2014 to 19 August 2014
  

Key stats and ratios

Q1 (Mar '14) 2014
Net profit margin -10.26% -6.30%
Operating margin -22.05% -16.99%
EBITD margin - 11.78%
Return on average assets -1.73% -0.99%
Return on average equity -2.19% -1.27%
Employees 215 -
CDP Score - 52 D

Address

One Prospect West
CHIPPENHAM, SN14 6FH
United Kingdom - Map
+44-1249-667700 (Phone)
+44-1249-667701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura�s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company�s pharmaceutical business consists of the research, development and commercialization of pharmaceutical products. Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development. The Company�s products include NVA237, QVA149, VR315 EU & RoW, VR315 US, VR632 EU, VR632 US & RoW and VR315. Vectura has development collaborations and license agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). In March 2014, Vectura Group Plc acquired Activaero GmbH.

Officers and directors

Chris Paul Blackwell Ph.D. Chief Executive, Executive Director
Age: 52
Paul Oliver Chief Financial Officer, Company Secretary, Director
Age: 36
Trevor Michael Phillips Ph.D. Chief Operating Officer, President - US Operations, Director
Age: 53
Gerard Scheuch Chief Scientific Officer
Age: 58
Roger Heerman Chief Commercial Officer
Age: 41
Karl D. Keegan Ph.D. Chief Corporate Development Officer
Age: 47
Bruno F. J. Angelici Non-Executive Chairman of the Board
Age: 67
John Robert Brown Ph.D., CBE Senior Independent Non-Executive Director
Age: 59
Susan Elizabeth Foden Ph.D. Non-Executive Independent Director
Age: 61
Neil William Warner Non-Executive Independent Director
Age: 61